Terumo Cardiovascular Group

e-mail usprint

Post-op Atrial Fibrillation

Clinicians are adopting a variety of therapies to reduce the incidence rate of new-onset post-operative atrial fibrillation, estimated at 30 to 40 percent in U.S. cardiac surgery patients.

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

SYNOPSIS: European Team Outlines Benefits Of Minimized Perfusion Circuit
At the Optimizing Cardiac Surgery Symposium on March 5, 2010, Uwe Schonrock, CCP, Klinikum Braunschweig, shared the clinical benefits of his team's use of the ROCSafe Hybrid Perfusion System in 2,500 cases.

ABSTRACT: Improving Cardiac Surgery Outcomes: Leukocyte Filtration
Amit Patel, MD, presents his outcome data on 2,000 patients undergoing cardiac surgery with leukocyte filtration at the July 2004 Hammersmith Meeting.

ABSTRACT: Leukocyte Filtration and Aprotinin: Synergistic Anti-Inflammatory Protection. Perfusion 2004; Volume 19. O-Yurvati A.
In this follow-up study, Albert O-Yurvati, DO, compares the effects of leukocyte filtration combined with aprotinin versus aprotinin alone to reduce post-operative atrial fibrillation in patients undergoing CPB.

ABSTRACT: Intraoperative Treatment Strategy to Reduce the Incidence of Post-Cardiopulmonary Bypass Atrial Fibrillation. Perfusion 2002; V 17. O-Yurvati A.
In this study, the authors demonstrate a 72% reduction in the incidence of post-op atrial fibrillation in patients who receive leukocyte filtration and aprotinin, resulting in $8,725 savings per patient.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: Clinical Evaluation of a Leuko-Depleting Blood Cardioplegia Filter (BC1B) for Elective Open-Heart Surgery. Perfusion 1998; 13: 205-210. Suzuki, et al.
In this study of 40 CABG patients, the authors demonstrate the ability of the Pall BC1 filter to remove inflammatory mediators CPK-MB and troponin.